Blood Pressure Disorders Drug Development Pipeline Review, 2018

Blood Pressure Disorders Drug Development Pipeline Review, 2018


  • Products Id :- GBIHC043IDB
  • |
  • Pages: 213
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Blood Pressure Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels.

Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases. Companies operating in this pipeline space include Gmax Biopharm, Actelion Pharmaceuticals and Theravance Biopharma.

Scope

- Which companies are the most active within the pipeline for blood pressure disorders?

- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 10

2.1 Blood Pressure Disorder Report Coverage 10

2.2 Hypertension-Overview 10

2.3 Hypotension-Overview 10

2.4 Pulmonary Arterial Hypertension-Overview 10

3 Therapeutics Development 11

3.1 Hypertension 11

3.2 Hypotension 32

3.3 Pulmonary Arterial Hypertension 35

4 Therapeutics Assessment 45

4.1 Hypertension 45

4.2 Hypotension 61

4.3 Pulmonary Arterial Hypertension 67

5 Companies Involved in Therapeutics Development 77

5.1 Hypertension 77

5.2 Hypotension 129

5.3 Pulmonary Arterial Hypertension 131

6 Dormant Projects 156

6.1 Hypertension 156

6.2 Hypotension 169

6.3 Pulmonary Arterial Hypertension 169

7 Discontinued Products 173

7.1 Hypertension 173

7.2 Pulmonary Arterial Hypertension 175

8 Product Development Milestones 176

8.1 Hypertension 176

8.2 Hypotension 187

8.3 Pulmonary Arterial Hypertension 197

9 Appendix 212

9.1 Methodology 212

9.2 Coverage 212

9.3 Secondary Research 212

9.4 Primary Research 212

9.5 Expert Panel Validation 212

9.6 Contact Us 213

9.7 Disclaimer 213

1.2 List of Figures

Figure 1: Number of Products under Development for Hypertension 11

Figure 2: Number of Products under Development by Companies Hypertension 12

Figure 3: Number of Products under Development by Universities/Institutes Hypertension 17

Figure 4: Number of Products under Development for Hypotension 32

Figure 5: Number of Products under Development by Companies Hypotension 33

Figure 6: Number of Products under Development for Pulmonary Arterial Hypertension 35

Figure 7: Number of Products under Development by Companies Pulmonary Arterial Hypertension 36

Figure 8: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39

Figure 9: Number of Products by Top 10 Targets Hypertension 45

Figure 10: Number of Products by Stage and Top 10 Targets Hypertension 45

Figure 11: Number of Products by Top 10 Mechanism of Actions Hypertension 51

Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions Hypertension 51

Figure 13: Number of Products by Top 10 Routes of Administration Hypertension 57

Figure 14: Number of Products by Stage and Top 10 Routes of Administration Hypertension 57

Figure 15: Number of Products by Top 10 Molecule Types Hypertension 59

Figure 16: Number of Products by Stage and Top 10 Molecule Types Hypertension 59

Figure 17: Number of Products by Targets Hypotension 61

Figure 18: Number of Products by Stage and Targets Hypotension 61

Figure 19: Number of Products by Mechanism of Actions Hypotension 62

Figure 20: Number of Products by Stage and Mechanism of Actions Hypotension 63

Figure 21: Number of Products by Routes of Administration Hypotension 64

Figure 22: Number of Products by Stage and Routes of Administration Hypotension 64

Figure 23: Number of Products by Molecule Types Hypotension 65

Figure 24: Number of Products by Stage and Molecule Types Hypotension 66

Figure 25: Number of Products by Top 10 Targets Pulmonary Arterial Hypertension 67

Figure 26: Number of Products by Stage and Top 10 Targets Pulmonary Arterial Hypertension 67

Figure 27: Number of Products by Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70

Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70

Figure 29: Number of Products by Routes of Administration Pulmonary Arterial Hypertension 73

Figure 30: Number of Products by Stage and Routes of Administration Pulmonary Arterial Hypertension 74

Figure 31: Number of Products by Top 10 Molecule Types Pulmonary Arterial Hypertension 75

Figure 32: Number of Products by Stage and Top 10 Molecule Types Pulmonary Arterial Hypertension 76

1.1 List of Tables

Table 1: Number of Products under Development for Hypertension 11

Table 2: Number of Products under Development by Companies Hypertension 13

Table 3: Number of Products under Development by Universities/Institutes Hypertension 18

Table 4: Products under Development by Companies Hypertension 19

Table 5: Products under Development by Universities/Institutes Hypertension 30

Table 6: Number of Products under Development for Hypotension 32

Table 7: Number of Products under Development by Companies Hypotension 33

Table 8: Products under Development by Companies Hypotension 34

Table 9: Number of Products under Development for Pulmonary Arterial Hypertension 35

Table 10: Number of Products under Development by Companies Pulmonary Arterial Hypertension 37

Table 11: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39

Table 12: Products under Development by Companies Pulmonary Arterial Hypertension 40

Table 13: Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 44

Table 14: Number of Products by Stage and Target Hypertension 46

Table 15: Number of Products by Stage and Mechanism of Action Hypertension 52

Table 16: Number of Products by Stage and Route of Administration Hypertension 58

Table 17: Number of Products by Stage and Molecule Type Hypertension 60

Table 18: Number of Products by Stage and Target Hypotension 62

Table 19: Number of Products by Stage and Mechanism of Action Hypotension 63

Table 20: Number of Products by Stage and Route of Administration Hypotension 65

Table 21: Number of Products by Stage and Molecule Type Hypotension 66

Table 22: Number of Products by Stage and Target Pulmonary Arterial Hypertension 68

Table 23: Number of Products by Stage and Mechanism of Action Pulmonary Arterial Hypertension 71

Table 24: Number of Products by Stage and Route of Administration Pulmonary Arterial Hypertension 75

Table 25: Number of Products by Stage and Molecule Type Pulmonary Arterial Hypertension 76

Table 26: Hypertension-Pipeline by A1M Pharma AB 77

Table 27: Hypertension-Pipeline by Acceleron Pharma Inc 77

Table 28: Hypertension-Pipeline by Ache Laboratorios Farmaceuticos SA 78

Table 29: Hypertension-Pipeline by Actelion Pharmaceuticals Ltd 78

Table 30: Hypertension-Pipeline by Aerogen Ltd 79

Table 31: Hypertension-Pipeline by Anavex Life Sciences Corp 79

Table 32: Hypertension-Pipeline by AnGes Inc 80

Table 33: Hypertension-Pipeline by Arena Pharmaceuticals Inc 80

Table 34: Hypertension-Pipeline by Ascendia Pharmaceuticals LLC 81

Table 35: Hypertension-Pipeline by Ascendis Pharma A/S 81

Table 36: Hypertension-Pipeline by AVEO Pharmaceuticals Inc 82

Table 37: Hypertension-Pipeline by Bayer AG 82

Table 38: Hypertension-Pipeline by Bial-Portela & Ca SA 83

Table 39: Hypertension-Pipeline by Bioblue Technologies Inc 83

Table 40: Hypertension-Pipeline by Biogen Inc 83

Table 41: Hypertension-Pipeline by Biolab Farmaceutica Ltda 84

Table 42: Hypertension-Pipeline by BioRestorative Therapies Inc 84

Table 43: Hypertension-Pipeline by Boryung Pharmaceutical Co Ltd 85

Table 44: Hypertension-Pipeline by Bristol-Myers Squibb Co 85

Table 45: Hypertension-Pipeline by Camurus AB 86

Table 46: Hypertension-Pipeline by Capricor Therapeutics Inc 86

Table 47: Hypertension-Pipeline by Celsion Corp 87

Table 48: Hypertension-Pipeline by Celtaxsys Inc 87

Table 49: Hypertension-Pipeline by Chiesi Farmaceutici SpA 88

Table 50: Hypertension-Pipeline by Chong Kun Dang Pharmaceutical Corp 88

Table 51: Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd 89

Table 52: Hypertension-Pipeline by CJ HealthCare Corp 89

Table 53: Hypertension-Pipeline by Complexa Inc 89

Table 54: Hypertension-Pipeline by Corion Biotech Srl 90

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

A1M Pharma AB

Acceleron Pharma Inc

Ache Laboratorios Farmaceuticos SA

Actelion Pharmaceuticals Ltd

Aerogen Ltd

Anavex Life Sciences Corp

AnGes Inc

Arena Pharmaceuticals Inc

Ascendia Pharmaceuticals LLC

Ascendis Pharma A/S

AVEO Pharmaceuticals Inc

Bayer AG

BCO Pharma Ltd

Bial - Portela & Ca SA

Bioblue Technologies Inc

Biogen Inc

Biolab Farmaceutica Ltda

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Cerecor Inc

Chiesi Farmaceutici SpA

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

CJ HealthCare Corp

Complexa Inc

Corion Biotech Srl

Cumberland Pharmaceuticals Inc

D. Western Therapeutics Institute Inc

Daewon Pharm Co Ltd

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Denovo Biopharma LLC

Eli Lilly and Co

Esperion Therapeutics Inc

FunPep Co Ltd

Galectin Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

H. Lundbeck AS

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Hypotension

Idorsia Pharmaceutical Ltd

Ildong Pharmaceutical Co Ltd

Innopharmax Inc

Insmed Inc

Insys Therapeutics Inc

Ionis Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

KBP BioSciences Co Ltd

La Jolla Pharmaceutical Company

Leading BioSciences Inc

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LG Chem Ltd

LinXis BV

Liquidia Technologies Inc

MannKind Corp

Marina Biotech Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

N4 Pharma Plc

Nippon Shinyaku Co Ltd

Nissan Chemical Industries Ltd

Northern Therapeutics Inc

Novartis AG

Omeros Corp

Orion Corporation

Peloton Therapeutics Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Pulmokine Inc

Pulmonary Arterial Hypertension

Quantum Genomics SA

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Relypsa Inc

Renova Therapeutics Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

rEVO Biologics Inc

Roivant Sciences Ltd

Rottapharm Biotech Srl

Sanofi

Sarfez Pharmaceuticals Inc

Serodus ASA

Shanghai Pharmaceutical Co Ltd

SJT Molecular Research SL

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

The Medicines Company

Theracos Inc

Theravance Biopharma Inc

Toray Industries Inc

TrioxBio Inc

United Therapeutics Corp

Vascular BioSciences

VG Life Sciences Inc

Vicore Pharma AB

Vivus Inc

XuanZhu Pharma Co Ltd

Yuhan Corp

select a license
Single User License
USD 3995 INR 291236
Site License
USD 7990 INR 582471
Corporate User License
USD 11985 INR 873707

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com